臨床試驗

First-in-Human Study of the Radioligand 68Ga- DOTA-EphA2

NCT：NCT07593209 · RECRUITING

NCT IDNCT07593209

狀態RECRUITING

開始日期2026-05-01

完成時間2027-12-31

SponsorFirst Hospital of China Medical University (OTHER)

First posted2026-05-18

Last updated2026-05-18

簡要摘要

Purpose Ephrin type-A receptor 2 (EphA2) is a receptor tyrosine kinase overexpressed in various solid tumors and associated with tumor progression, metastasis, and poor prognosis. However, noninvasive imaging tools for assessing EphA2 expression in vivo remain limited. This study aims to develop a novel 68Ga-labeled EphA2-targeting positron emission tomography (PET) tracer for specific imaging of EphA2-positive malignancies.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。